Reiterating Buy On SRNE重申买入SRNE

Sorrento Therapeutics, Inc., (SRNE 9.98 +19.38%) is a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. 

SRNE has already included in our Diversified Portfolio since August 5 this year ( https://tradeideablog.blogspot.com/2020/08/a-diversified-aggressive-growth.html)  and today is a good time to buy more.

Positives for SRNE:

1.Sorrento receives US FDA clearance to proceed with Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 positive patients. Sorrento noted in its press release that an EUA application could be submitted to FDA for approval.

2.Other near term catalysts are:

COVI-TRACE™ Diagnostic Test:FDA Emergency Use Authorization (EUA) Application Expected

COVI-TRACK™ Antibody Test:FDA Emergency Use Authorization (EUA) Application Under Review

3.The company has 13 other things in the development pipeline. Its ABIVERTINIB for Immunotherapy is in Phase III trial.

4. Technically it has formed a most bullish Island Reversal chart pattern. Near term price targets are $12-14. It was at $19.39 on August 10 this year.

5. It has 34% shorted shares and short squeeze will likely forces price higher.

Sorrento Therapeutics，Inc.（SRNE 9.98 +19.38%)是一家临床生物制药公司，致力于开发用于癌症，自身免疫，炎性和神经退行性疾病的疗法。

自今年8月5日以来，SRNE已经包含在我们的多元化投资组合中（https://tradeideablog.blogspot.com/2020/08/a-diversified-aggressive-growth.html），而今天是购买更多股票的好时机。

SRNE的优势：

1，SRNE获得美国FDA批准，可在COVID-19阳性患者中进行STI-1499（COVI-GUARD）中和抗体的1期临床试验。SRNE在其新闻稿中指出，可以在年底前将EUA申请提交给FDA批准。

2，其他近期催化剂是：

COVI-TRACE™诊断测试：有望获得FDA紧急使用授权（EUA）应用

COVI-TRACK™抗体测试：正在审查FDA紧急使用授权（EUA）应用

3.公司还有其他13项产品正在开发中。 其用于免疫疗法的ABIVERTINIB处于III期试验中。

4.从技术上讲，它已经形成了最看涨的岛形向上反转图表形态。 近期目标价为12-14美元。今年 8月10日时价格为19.39美元。

5.它有34％的空头股票，而空头挤压很可能会迫使价格上涨。